Phase II Randomized Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy Induced Esophagitis-Related Pain During the Treatment of Lung Cancer
RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy and radiation therapy. It is not yet known whether Manuka honey is more effective than standard care in preventing pain. PURPOSE: This randomized phase II clinical trial is studying Manuka honey to see how well it works in preventing esophagitis-related pain in patients receiving chemotherapy and radiation therapy for lung cancer.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- Quynh-Thu Le, MD, FACR, FASTRO
- Joel Neal, MD, PhD
- Maximilian Diehn, MD, PhD
- Billy W. Loo, Jr., MD, PhD, DABR
- Wendy Hara
- Kavitha Ramchandran
- Heather Wakelee, MD
- drug : Viscous lidocaine and magnesium aluminum oxide (Maalox®); Liquid or solid oxycodone
- drug : Manuka honey
Phase: Phase 2
Ages Eligible For Study: